Kampanjeplan Carmell Therapeutics Corporation
Avansert tidsplan
Enkel graf
Om selskapet
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
| EBITDA |
-0.0017 |
| EV/EBITDA |
-5.82 |
| IPO date |
2023-07-17 |
| ISIN |
US1429221039 |
| Industry |
Biotechnology |
| P/BV |
1.7 |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Выручка |
0.0037 |
| Сайт |
https://www.carmellrx.com
|
| Цена ао |
2.9 |
| Число акций ао |
0.01102 млрд |
| Prisendring per dag: |
-5.09% (0.322) |
| Prisendring per uke: |
+38.66% (0.2204) |
| Prisendring per måned: |
+10.72% (0.276) |
| Prisendring over 3 måneder: |
-17.41% (0.37) |
| Prisendring over seks måneder: |
-83.02% (1.8) |
| Prisendring per år: |
-91.98% (3.81) |
| Prisendring over 3 år: |
-96.84% (9.68) |
| Prisendring over 5 år: |
0% (0.3056) |
| Prisendring over 10 år: |
0% (0.3056) |
| Prisendring siden begynnelsen av året: |
+32.87% (0.23) |
|
|
Undervurdering
| Navn |
Betydning |
Karakter |
| P/S |
0 |
0 |
| P/BV |
1.71 |
8 |
| P/E |
0 |
0 |
| EV/EBITDA |
-8.18 |
0 |
| Total: |
|
4.63 |
|
Effektivitet
| Navn |
Betydning |
Karakter |
| ROA, % |
-24.15 |
0 |
| ROE, % |
-62.41 |
0 |
| Total: |
|
0 |
|
|
|
Utbytte
| Navn |
Betydning |
Karakter |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| Total: |
|
0 |
|
Plikt
| Navn |
Betydning |
Karakter |
| Debt/EBITDA |
-0.4195 |
10 |
| Total: |
|
10 |
|
Vekstimpuls
| Navn |
Betydning |
Karakter |
| Lønnsomhet Revenue, % |
0 |
0 |
| Lønnsomhet Ebitda, % |
310.57 |
10 |
| Lønnsomhet EPS, % |
316.09 |
10 |
| Total: |
|
8 |
|
| Veileder |
Stillingstittel |
Betaling |
Fødselsår |
| Mr. Rajiv Sarman Shukla |
Executive Chairman |
292.19k |
1975 (50 år) |
| Dr. Phil Campbell Ph.D. |
Founder and Chief Scientific Officer |
N/A |
|
| Dr. Lee Weiss Ph.D. |
Founder |
N/A |
|
| Dr. James Burgess M.D. |
Founder |
N/A |
|
| Mr. Bryan J. Cassaday |
Chief Financial Officer |
261.7k |
1969 (56 år) |
| Ms. Kendra Bracken-Ferguson |
Chief Executive Officer |
|
|
